Manganese-based magnetic resonance contrast agents

Patent metadata

Field	Value
Publication number	US-9944668-B2
Application number	US-201414759114-A
Country	US
Kind code	B2
Filing date	Jan 7, 2014
Priority date	Jan 7, 2013
Publication date	Apr 17, 2018
Grant date	Apr 17, 2018

Abstract

Manganese coordination complexes with utility as magnetic resonance probes and as biological reductant sensors are disclosed. In one embodiment, ligands can stabilize both the Mn 2+ and Mn 3+ oxidation states. In the presence of a reductant such as glutathione, low relaxivity Mn III -HBET is rapidly converted to high relaxivity Mn II -HBET with a 3-fold increase in relaxivity, and concomitant increase in magnetic resonance signal. In another embodiment, ligands were designed to chelate Mn(ll) in a thermodynamically stable and kinetically inert fashion while allowing for direct interaction of Mn(ll) with water. In yet another embodiment, high molecular weight multimers containing six Mn(ll) chelators were prepared. The high molecular weight results in slower tumbling of the molecules in solution and can strongly enhance the Mn(ll) relaxivity.

First claim

What is claimed is:

1. A contrast agent for magnetic resonance imaging, the contrast agent comprising a compound of Formula (IX):

2. The contrast agent of claim 1 , wherein the Mn is a positron emitting manganese isotope.

3. A pharmaceutical composition, comprising the contrast agent of claim 1 and a pharmaceutically acceptable carrier.

4. The pharmaceutical composition of claim 3 , further comprising an additional pharmaceutically active ingredient.

5. A method of diagnostic imaging, comprising administering to a subject a contrast agent comprising a compound of Formula (IX):

6. The method of claim 5 , wherein the diagnostic technique is selected from among the group consisting of magnetic resonance imaging (MM), positron emission tomography (PET), and concurrent Mill and PET.

7. The method of claim 5 , wherein the Mn is a positron emitting manganese isotope.

8. The method of claim 5 , wherein the contrast agent is administered directly to a tissue being diagnostically imaged, to a body fluid that contacts a tissue being diagnostically imaged, or to a body location from which the contrast agent can diffuse or be transported to a tissue being diagnostically imaged.

9. The method of claim 5 , wherein the contrast agent is administered intravenously, intramuscularly, subcutaneously, intracerebrally, or intrathecally.

Assignees

• Caravan Peter
• Gale Eric M
• Loving Galen S
• Mukherjee Shereya
• Zhu Jiang
• Massachusetts Gen Hospital

Inventors

• Caravan Peter
• Gale Eric M
• Loving Galen S
• Mukherjee Shereya
• Zhu Jiang

Classifications

• C07F13/005 Primary

  Compounds without a metal-carbon linkage · CPC title

• A61B5/055

  involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging · CPC title

• A61K49/103

  the complex-forming compound being acyclic, e.g. DTPA · CPC title

• A61K51/04

  Organic compounds · CPC title

• A61K51/0455

  having six-membered rings with one nitrogen as the only ring hetero atom · CPC title